New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer

Louisa S Chard; Nicholas R Lemoine; Yaohe Wang

doi:10.1080/2162402X.2015.1038689

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer

Oncoimmunology. 2015 Jul 20;4(9):e1038689. doi: 10.1080/2162402X.2015.1038689. eCollection 2015 Sep.

Authors

Louisa S Chard¹, Nicholas R Lemoine², Yaohe Wang²

Affiliations

¹ Center for Molecular Oncology; Barts Cancer Institute; Queen Mary University of London ; London, UK.
² Center for Molecular Oncology; Barts Cancer Institute; Queen Mary University of London ; London, UK ; Sino-British Research Centre for Molecular Oncology; National Centre for International Research in Cell and Gene Therapy; Zhengzhou University ; Zhengzhou, China.

Abstract

Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows promising potential for treatment of pancreatic cancer (PaCa).

Keywords: IL-10; immunotherapy; oncolytic virus; pancreatic cancer; vaccinia virus.

Publication types

Research Support, Non-U.S. Gov't

Abstract

Publication types

Grants and funding